Fertility-sparing Surgery in Early-stage Cervical Cancer: Indications and Applications
Overview
Authors
Affiliations
This article describes the surgical and pathologic findings of fertility-sparing radical trachelectomy using a standardized surgical technique, and reports the rate of posttrachelectomy outcomes. The authors analyzed a prospectively maintained database of all patients with FIGO stage IA1-IB1 cervical cancer admitted to the operating room for planned fertility-sparing radical abdominal trachelectomy. Sentinel node mapping was performed through cervical injection. Between November 2001 and May 2010, 98 consecutive patients with FIGO stage IA1-IB1 cervical cancer and a median age of 32 years (range, 6-45 years) underwent a fertility-sparing radical trachelectomy. The most common histology was adenocarcinoma in 54 patients (55%) and squamous carcinoma in 42 (43%). Lymph-vascular invasion was seen in 38 patients (39%). FIGO stages included IA1 (with lymph-vascular invasion) in 10 patients (10%), IA2 in 9 (9%), and IB1 in 79 (81%). Only 15 (15%) needed immediate completion radical hysterectomy because of intraoperative findings. Median number of nodes evaluated was 22 (range, 3-54), and 16 (16%) patients had positive pelvic nodes on final pathology. Final trachelectomy pathology showed no residual disease in 44 (45%) cases, dysplasia in 5 (5%), and adenocarcinoma in situ in 3 (3%). Overall, 27 (27%) patients needed hysterectomy or adjuvant pelvic radiation postoperatively. One (1%) documented recurrence was fatal at the time of this report. Cervical adenocarcinoma and lymph-vascular invasion are common features of patients selected for radical trachelectomy. Most patients can undergo the operation successfully with many having no residual invasive disease; however, nearly 27% of all selected cases will require hysterectomy or postoperative chemoradiation for oncologic reasons. Investigation into alternative fertility-sparing adjuvant therapy in patients with node-positive disease is needed.
Jiang X, Feng C, Sun W, Zhang T, Cui B Heliyon. 2024; 10(11):e31738.
PMID: 38828299 PMC: 11140800. DOI: 10.1016/j.heliyon.2024.e31738.
Fertility-sparing options for cancer patients.
Alur-Gupta S, Fruchtman H, Paroder V Abdom Radiol (NY). 2023; 48(5):1618-1628.
PMID: 36884058 DOI: 10.1007/s00261-023-03839-8.
Yong N, Cooper N, Yorke S, Baran C, Khan K, Tan A BJOG. 2022; 130(2):163-175.
PMID: 36367451 PMC: 10108142. DOI: 10.1111/1471-0528.17342.
[Uterine Cervical Cancer: Emphasis on Revised FIGO Staging 2018 and MRI].
Jang W, Song J Taehan Yongsang Uihakhoe Chi. 2022; 82(5):1083-1102.
PMID: 36238389 PMC: 9432380. DOI: 10.3348/jksr.2021.0113.
Fertility-Sparing Surgery in Gynecologic Cancer: A Systematic Review.
Schuurman T, Zilver S, Samuels S, Schats W, Amant F, van Trommel N Cancers (Basel). 2021; 13(5).
PMID: 33670929 PMC: 7975326. DOI: 10.3390/cancers13051008.